InsiderTrades.com logo
When it comes to NVDA… “acceleration cycles” are the key
From DTI   |   Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!
Lai Wang net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Lai Wang Biography and Net Worth

Insider of BeiGene
Lai Wang, Ph.D., is our Global Head of R&D. Dr. Wang joined BeiGene in the early days of the company, 2011. His role has changed over the years within the organization, initially heading the biomarker and in vivo pharmacology groups. In 2013, he supported the clinical programs in the role of clinical biomarkers and translational research. In 2016, he was appointed as the head of China development, responsible for the clinical development in Asian-pacific region. Prior to joining BeiGene, Dr. Wang was the director of research at Joyant Pharmaceuticals, a biotech company based in Dallas, Texas. Dr. Wang received his B.S. from Fudan University and Ph.D. from University of Texas Health Science Center at San Antonio, and had post-doc training with Dr. Xiaodong Wang at Howard Hughes Medical Institute. Dr. Wang had over 20 years of experience in oncology field and over 10 years of experience in pharmaceutical industry on both research and development.

What is Lai Wang's net worth?

The estimated net worth of Lai Wang is at least $178.90 million as of September 27th, 2024. Dr. Wang owns 920,920 shares of BeiGene stock worth more than $178,897,919 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Wang may own. Additionally, Dr. Wang receives a salary of $996,920.00 as Insider at BeiGene. Learn More about Lai Wang's net worth.

How old is Lai Wang?

Dr. Wang is currently 47 years old. There are 2 older executives and no younger executives at BeiGene. The oldest executive at BeiGene is Dr. Xiaobin Wu Ph.D., President & COO, who is 62 years old. Learn More on Lai Wang's age.

What is Lai Wang's salary?

As the Insider of BeiGene, Ltd., Dr. Wang earns $996,920.00 per year. There are 2 executives that earn more than Dr. Wang. The highest earning executive at BeiGene is Mr. John V. Oyler, Co-Founder, Executive Chairman & CEO, who commands a salary of $2,050,000.00 per year. Learn More on Lai Wang's salary.

How do I contact Lai Wang?

The corporate mailing address for Dr. Wang and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Lai Wang's contact information.

Has Lai Wang been buying or selling shares of BeiGene?

Lai Wang has not been actively trading shares of BeiGene during the past quarter. Most recently, Lai Wang sold 5,000 shares of the business's stock in a transaction on Friday, September 27th. The shares were sold at an average price of $220.35, for a transaction totalling $1,101,750.00. Following the completion of the sale, the insider now directly owns 920,920 shares of the company's stock, valued at $202,924,722. Learn More on Lai Wang's trading history.

Who are BeiGene's active insiders?

BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.

Are insiders buying or selling shares of BeiGene?

During the last twelve months, insiders at the sold shares 16 times. They sold a total of 95,368 shares worth more than $16,313,435.19. The most recent insider tranaction occured on October, 8th when CEO John Oyler sold 6,175 shares worth more than $1,433,958.50. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.

Information on this page was last updated on 10/8/2024.

Lai Wang Insider Trading History at BeiGene

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/27/2024Sell5,000$220.35$1,101,750.00920,920View SEC Filing Icon  
6/24/2024Sell1,064$159.80$170,027.20View SEC Filing Icon  
6/26/2023Sell1,108$181.92$201,567.36View SEC Filing Icon  
6/20/2023Sell1,325$192.42$254,956.50View SEC Filing Icon  
6/7/2023Sell462$224.74$103,829.88View SEC Filing Icon  
6/27/2022Sell458$177.32$81,212.56View SEC Filing Icon  
6/21/2022Sell723$149.01$107,734.23View SEC Filing Icon  
6/17/2022Sell445$139.40$62,033.00723View SEC Filing Icon  
6/6/2022Sell660$142.00$93,720.00View SEC Filing Icon  
6/28/2021Sell455$362.48$164,928.40View SEC Filing Icon  
6/7/2021Sell656$354.26$232,394.56195,455View SEC Filing Icon  
See Full Table

Lai Wang Buying and Selling Activity at BeiGene

This chart shows Lai Wang's buying and selling at BeiGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BeiGene Company Overview

BeiGene logo
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Read More

Today's Range

Now: $194.26
Low: $192.00
High: $198.48

50 Day Range

MA: $212.60
Low: $187.69
High: $246.04

2 Week Range

Now: $194.26
Low: $126.97
High: $248.16

Volume

261,727 shs

Average Volume

265,949 shs

Market Capitalization

$18.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63
When it comes to NVDA… “acceleration cycles” are the key
From DTI   |   Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!